Abstract:The involvement of platelets in tumor progression is well recognized. The depletion of circulating platelets or pharmacologic inhibitors of platelet activation decreases the metastatic potential of circulating tumor cells in metastasis mouse models. The platelet ADP receptor P2Y12 amplifies the initial hemostatic responses activated by a variety of platelet agonists and stabilizes platelet aggregation, playing a crucial role in granule secretion, integrin activation and thrombus formation. However, the relationship between P2Y12 and tumor progression is not clear. In our study, the Lewis Lung Carcinoma (LLC) spontaneous metastatic mouse model was used to evaluate the role of P2Y12 in metastasis. The results demonstrated that P2Y12 deficiency significantly reduced pulmonary metastasis. Further studies indicated that P2Y12 deficiency diminished the ability of LLC cells to induce platelet shape change and release of active TGFβ1 by a non-contact dependent mechanism resulting in a diminished, platelet-induced EMT-like transformation of the LLC cells, and that transformation probably is a prerequisite of LLC cell metastasis. Immunohistochemical analyses indicated an obvious P2Y12 deficiency related attenuation of recruitment of VEGFR1+ bone marrow derived cell clusters, and extracellular matrix fibronectin deposition in lungs, which presumably are required for pre-metastatic niche formation. In contrast to the LLC cells, non-epithelial melanoma B16 cells induced platelet aggregation in a cell number and P2Y12-dependent manner. Also, a platelet induced EMT-like transformation of B16 cells is dependent on P2Y12. In agreement with the LLC cell model, platelet P2Y12 deficiency also results in significantly less lung metastasis in the B16 melanoma experimental metastasis model. These results demonstrate that P2Y12 is a safe drug target for anti-thrombotic therapy, and that P2Y12 may serve as a new target for inhibition of tumor metastasis.

A Humanized Single-Chain Antibody Against Beta 3 Integrin Inhibits Pulmonary Metastasis by Preferentially Fragmenting Activated Platelets in the Tumor Microenvironment

Novel Antibodies Against GPIb Alpha Inhibit Pulmonary Metastasis by Affecting Vwf-Gpib Alpha Interaction

Novel Antibodies Against Glycoprotein Ibα Inhibit Pulmonary Metastasis by Affecting Vwf-Gpibα Interaction

Disrupting Tumour Vasculature and Recruitment of Apdl1-Loaded Platelets Control Tumour Metastasis

Platelet P2Y12 is Involved in Murine Pulmonary Metastasis.

Modified Heparins Inhibit Integrin Αiibβ3 Mediated Adhesion of Melanoma Cells to Platelets in Vitro and in Vivo

Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus

Tumor metastasis inhibitor of targeted mouse platelet membrane glycoprotein GPIb alpha and identification method of inhibitor

Targeted Inhibition of Tumor Inflammation and Tumor-Platelet Crosstalk by Nanoparticle-Mediated Drug Delivery Mitigates Cancer Metastasis.

Combined inhibition of S100A4 and TIGIT suppresses late-stage breast cancer metastasis to the lung by activating T and NK cells

A Novel Target Anti-Interleukin-13 Receptor Subunit Alpha-2 Monoclonal Antibody Inhibits Tumor Growth and Metastasis in Lung Cancer.

Targeted platelet membrane glycoprotein GPIbalpha monoclonal antibody for inhibiting tumor metastasis and screening method thereof

A multifunctional antibody fusion protein 57103 targeting CD24, IL-4R, and αvβ3 for treating cancer and regulating the tumor microenvironment

Platelets as platforms for inhibition of tumor recurrence post-physical therapy by delivery of anti-PD-L1 checkpoint antibody.

Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor

Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis

A humanized single-chain variable fragment antibody against beta3 integrin in Escherichia coli.

[Intraperitoneal injection of human-derived anti-c-Met single-chain antibody inhibits the growth of transplanted tumours in A549 lung adenocarcinoma-loaded mice]

In Situ Activation of Platelets with Checkpoint Inhibitors for Post-Surgical Cancer Immunotherapy

Inhibition of Platelet Function Using Liposomal Nanoparticles Blocks Tumor Metastasis.

Modified heparins inhibit integrin α<sub>IIb</sub>β<sub>3</sub>mediated adhesion of melanoma cells to platelets<i>in vitro</i>and<i>in vivo</i>